<DOC>
	<DOCNO>NCT00785863</DOCNO>
	<brief_summary>In addition alleviate pain grow evidence Âµ-opioids enhance pain . This problem know opioid induced hyperalgesia ( OIH ) .The NMDA receptor involve opioid induced hyperalgesia may possible block OIH cyclooxygenase inhibitor . This demonstrated parecoxib , COX-II inhibitor , experimental pain model.Both COX-1 COX-2 express spinal cord . It would interest investigate whether COX-1 prefer inhibitor like ketorolac also reduce opioid induce hyperalgesic experimental pain model .</brief_summary>
	<brief_title>Modulation Remifentanil-induced Postinfusion Hyperalgesia</brief_title>
	<detailed_description>Remifentanil fast act opioid become popular use surgery . There study , experimental 1-3 clinical 4 ; 5 , indicate remifentanil end infusion trigger enhance pain experience enhance opioid consumption postoperatively . Therefore important look possibility block enhance pain experience ( opioid induce hyperalgesia - OIH ) . Ketamin demonstrate block effect 5 ; 6 NMDA receptor . Unfortunately ketamin seriously side-effects like hallucination , therefore suitable ordenary clinical use . Recently , demonstrate parecoxib ( COX-2 inhibitor ) prevent remifentanil-induced postinfusion hyperalgesia study healthy volunteers.7 COX-2 inhibitor disadvantage longterm adverse effect like cardiac arrest . Therefore would interest look COX-1 preferring NSAID , like ketorolac , see also non-selective NSAIDs partly block remifentanil-induced postinfusion hyperalgesia . To investigate provoke pain secondary hyperalgesia use intradermal electrical pain model well established.1 ; 7-9 Detailed description model look reference 7 . H0 : Parecoxib prevents remifentanil postinfusion secondary hyperalgesi . Ketorolac prevent remifentanil postinfusion secondary hyperalgesi HA : Parecoxib ketorolac prevent remifentanil postinfusion secondary hyperalgesi .</detailed_description>
	<mesh_term>Hyperalgesia</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<mesh_term>Parecoxib</mesh_term>
	<mesh_term>Remifentanil</mesh_term>
	<criteria>Healthy volunteer Allergy drug use study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>hyperalgesia</keyword>
	<keyword>remifentanil</keyword>
	<keyword>ketorolac</keyword>
	<keyword>parecoxib</keyword>
	<keyword>COX-1 inhibitor</keyword>
	<keyword>COX-2 inhibitor</keyword>
</DOC>